Similarly, vaccination with anti-hDEC-205-NY-ESO-1 tumor antigen in conjunction with Toll-like receptor (TLR) agonists elicited an anti-tumor immune response and tumor regression in some patients with multiple advanced malignancies refractory to other therapies [146,147]. The gene discussed is LINC01194; the disease is neoplasm.